Milrinone Horizon 10mg/10 mL Concentrated Injection milrinone (as lactate)10mg/10 mL ampoule

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

milrinone, Quantity: 10 mg

Available from:

Generic Health Pty Ltd

INN (International Name):

Milrinone

Pharmaceutical form:

Injection, concentrated

Composition:

Excipient Ingredients: water for injections; lactic acid; sodium hydroxide; glucose

Administration route:

Intravenous

Units in package:

10 ampoules, 1 ampoule

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

- Milrinone Horizon Concentrated Injection is indicated for the short term (48 hours) intravenous therapy of severe congestive heart failure patients in intensive care and coronary care units not responding to other therapy (eg. digoxin, diuretics, vasodilators, including ACE inhibitors). The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. - Milrinone Horizon Concentrated Injection is also indicated for low output states following cardiac surgery, including weaning from cardio-pulmonary bypass pump.

Product summary:

Visual Identification: Clear, colourless to pale yellow sterile solution, practically free from visible particles.; Container Type: Ampoule; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Licence status A

Authorization date:

2013-11-29